Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

Inclusion Criteria: * Histologic diagnosis of epithelial ovarian or primary peritoneal cancer * Measurable disease or evaluable disease with CA125 \>100 * One prior treatment with taxane/platinum based chemotherapy, but patients with recurrent ovarian cancer not receiving platinum-based chemotherapy at time of initial diagnosis will be allowed * Recurrence after treatment free interval of at least 6 mos from completion of primary chemotherapy * 19 years of age or older * Life expectancy of greater than 12 weeks * Performance status of 0, 1 or 2 (based on GOG Performance Status) * Normal bone marrow, renal and hepatic function based upon lab tests * Cardiac ejection fraction within institutional normal range * Ability to swallow and retain oral medication * Ability to understand a written informed consent document Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering study * Epithelial ovarian tumors of low malignant potential, stromal or germ cell origin * Non-measurable or non-evaluable disease * Archived tumor tissue not available for assay * Patients may not be receiving any other investigational agents or concurrent anticancer therapy, or herbal (alternative) medicines * Patients with known brain metastases * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent. * Uncontrolled inter-current illness * Patients who are pregnant * HIV-positive patients receiving combination anti-retroviral therapy * Patients with GI tract disease resulting in an inability to take oral medication